Greenspring Advisors’s Quest Diagnostics DGX Stock Holding History

Greenspring Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$519K	Buy	2,448 +3	+0.1%	+$589	0.03%	196
2026 Q1	$479K	Buy	2,445 +3	+0.1%	+$583	0.03%	181
2025 Q4	$424K	Buy	2,442 +524	+27%	+$95.4K	0.03%	185
2025 Q3	$366K	Buy	+1,918	New	+$340K	0.06%	74
2025 Q1	$325K	Hold	1,918	–	–	0.08%	70
2024 Q4	$289K	Hold	1,918	–	–	0.06%	68
2024 Q3	$298K	Hold	1,918	–	–	0.07%	71
2024 Q2	$263K	Hold	1,918	–	–	0.06%	57
2024 Q1	$255K	Hold	1,918	–	–	0.06%	61
2023 Q4	$264K	Hold	1,918	–	–	0.07%	54
2023 Q3	$234K	Hold	1,918	–	–	0.07%	55
2023 Q2	$270K	Sell	1,918 -1,354	-41%	-$187K	0.08%	46
2023 Q1	$463K	Hold	3,272	–	–	0.1%	69
2022 Q4	$512K	Buy	3,272 +1,354	+71%	+$195K	0.14%	64
2022 Q3	$235K	Hold	1,918	–	–	0.07%	94
2022 Q2	$255K	Hold	1,918	–	–	0.08%	92
2022 Q1	$263K	Hold	1,918	–	–	0.07%	86
2021 Q4	$332K	Buy	+1,918	New	+$292K	0.09%	79

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Greenspring Advisors's DGX Position: Q2 2026 in Review

Greenspring Advisors increased its Quest Diagnostics (DGX) stake by 0.12% in Q2 2026, buying an estimated $589 and bringing the position to 2,448 shares worth $519K. The position accounts for 0.03% of the portfolio, ranked #196.

Greenspring Advisors first reported a position in DGX in Q4 2021 and has held it in 18 quarters since. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Greenspring Advisors held 2,448 shares of Quest Diagnostics worth $519K as of Q2 2026.
Greenspring Advisors bought 3 Quest Diagnostics shares in Q2 2026, an estimated $589.
Quest Diagnostics made up 0.03% of Greenspring Advisors's portfolio in Q2 2026, its #196 holding.
Greenspring Advisors first reported a position in Quest Diagnostics in Q4 2021 and has held it in 18 quarters since.
1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Greenspring Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.